Menu Search
Equities

Cloud DX Inc

699:DEU

Cloud DX Inc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cloud DX Inc. is a Canada-based remote patient monitoring company that is a Health Canada licensed, United States Food and Drug Administration registered medical device manufacturer and software developer offering a complete end-to-end virtual healthcare platform called Cloud DX Connected Health. The Company has developed and cleared through regulatory agencies a family of proprietary medical devices, each of which collects multiple vital signs. Its customers purchase Connected Health in order to remotely monitor patients with serious chronic illness, including chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF), as well as patients recovering from surgery and Covid-19 patients decanted from hospitals. Typical the Company’s customers include hospitals and provincial health authorities in Canada, and physician practices and hospitals in the United States.

  • Revenue in CAD (TTM)1.95m
  • Net income in CAD-9.86m
  • Incorporated2019
  • Employees--
  • Location
    Cloud DX Inc72 Victoria Street SouthKITCHENER N2G 4Y9CanadaCAN
  • Phone+1 (289) 488-1699
  • Websitehttps://www.clouddx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.